NYSE:MNK - Mallinckrodt Stock Price, Price Target & More

$13.52 +0.17 (+1.27 %)

(As of 04/26/2018 04:00 PM ET)

Previous Close$13.52

Today's Range$13.31 - $13.68

52-Week Range$13.05 - $49.12

Volume1.68 million shs

Average Volume3.66 million shs

Market Capitalization$1.16 billion

P/E Ratio1.81

Dividend YieldN/A

Beta1.12

About Mallinckrodt (NYSE:MNK)

Mallinckrodt public limited company develops, manufactures, markets, and distributes branded pharmaceutical products in Canada and the European Union, as well as in Latin American, the Middle Eastern, African, and the Asia-Pacific regions. The company markets branded pharmaceutical products for autoimmune and rare diseases in the specialty areas of neurology, rheumatology, nephrology, ophthalmology, and pulmonology; and immunotherapy and neonatal respiratory critical care therapies, as well as analgesics and gastrointestinal products. It offers H.P. Acthar Gel, an injectable drug for various indications, such as proteinuria, multiple sclerosis, infantile spasms, ophthalmic, neuromuscular disorders, dermatomyositis, polymyositis, rheumatology, and pulmonology; Inomax, a vasodilator to enhance oxygenation and reduce the need for extracorporeal membrane oxygenation; Ofirmev, an intravenous formulation of acetaminophen for pain management; Therakos, an immunotherapy treatment platform; and Amitiza for the treatment of chronic idiopathic constipation. The company is also developing StrataGraft, which is in Phase III and II clinical development for the treatment of burns; terlipressin for the treatment of hepatorenal syndrome; MNK-1411 for the treatment of Duchenne muscular dystrophy; Stannsoporfin, a heme oxygenase inhibitor for the treatment of jaundice; Xenon gas for inhalation; MNK-6105, an ammonia scavenger for the treatment of hepatic encephalopathy, a neuropsychiatric syndrome associated with hyperammonemia; VTS-270 that is in Phase III development for Niemann-Pick Type C, a neurodegenerative fatal disease; and CPP-1X/sulindac, which is in Phase III development for Familial Adenomatous Polyposis. Mallinckrodt public limited company markets its branded products to physicians, pharmacists, pharmacy buyers, hospital procurement departments, ambulatory surgical centers, and specialty pharmacies. The company is based in Staines-Upon-Thames, the United Kingdom.

Receive MNK News and Ratings via Email

Sign-up to receive the latest news and ratings for MNK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNYSE:MNK

CUSIPN/A

Webwww.mallinckrodt.com

Phone44-0-17-8463-6700

Debt

Debt-to-Equity Ratio0.98%

Current Ratio2.18%

Quick Ratio1.85%

Price-To-Earnings

Trailing P/E Ratio1.81

Forward P/E Ratio2.19

P/E Growth0.33

Sales & Book Value

Annual Sales$3.22 billion

Price / Sales0.36

Cash Flow$16.2892 per share

Price / Cash0.83

Book Value$68.65 per share

Price / Book0.20

Profitability

EPS (Most Recent Fiscal Year)$7.49

Net Income$2.13 billion

Net Margins66.25%

Return on Equity13.43%

Return on Assets4.95%

Miscellaneous

Employees3,900

Outstanding Shares86,350,000

How to Become a New Pot Stock Millionaire

Mallinckrodt (NYSE:MNK) Frequently Asked Questions

What is Mallinckrodt's stock symbol?

Mallinckrodt trades on the New York Stock Exchange (NYSE) under the ticker symbol "MNK."

How will Mallinckrodt's stock buyback program work?

Mallinckrodt announced that its board has initiated a stock buyback program on Sunday, April 9th 2017, which permits the company to repurchase $1,000,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to buy up to 18.5% of its stock through open market purchases. Stock repurchase programs are generally a sign that the company's management believes its shares are undervalued.

How were Mallinckrodt's earnings last quarter?

Mallinckrodt (NYSE:MNK) posted its quarterly earnings results on Tuesday, February, 27th. The company reported $2.01 earnings per share for the quarter, beating analysts' consensus estimates of $1.72 by $0.29. The business had revenue of $792.30 million for the quarter, compared to the consensus estimate of $769.91 million. Mallinckrodt had a net margin of 66.25% and a return on equity of 13.43%. Mallinckrodt's revenue was down 4.5% compared to the same quarter last year. During the same period in the previous year, the business posted $1.91 EPS. View Mallinckrodt's Earnings History.

When is Mallinckrodt's next earnings date?

Mallinckrodt is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Mallinckrodt.

What guidance has Mallinckrodt issued on next quarter's earnings?

Mallinckrodt issued an update on its FY earnings guidance on Tuesday, February, 27th. The company provided earnings per share (EPS) guidance of $6.00-6.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.14. The company issued revenue guidance of +3-6% to ~$.

What price target have analysts set for MNK?

18 equities research analysts have issued 12 month price objectives for Mallinckrodt's stock. Their forecasts range from $15.00 to $67.00. On average, they anticipate Mallinckrodt's stock price to reach $33.8333 in the next twelve months. View Analyst Ratings for Mallinckrodt.

What are Wall Street analysts saying about Mallinckrodt stock?

Here are some recent quotes from research analysts about Mallinckrodt stock:

1. Mizuho analysts commented, "We expect briefing documents to get posted on May 1. We are cautious heading into the panel for a number of reasons outlined below, and note that it represents the first read on the quality of the company’s due diligence process following its recent string of acquisitions that are aimed to diversify revenues away from Acthar. We reiterate our Neutral rating and $15 PT. Stannsoporfin vote has a reasonable amount of risk: (1) The NDA submission is based on results from a positive pivotal Phase 2b trial and supporting data from a second positive Phase 2b trial. (2) The pivotal trial evaluated two doses (3.0 mg/kg and 4.5 mg/kg), which did not show a dose response effect. (3) We don’t know much about safety or risk/reward in this fragile patient population. From a commercial standpoint, it is unclear to us if the drug will need to be dosed preventatively, or if can be used as a rescue med." (4/26/2018)
2. Cantor Fitzgerald analysts commented, "Positives from the quarter that support our thesis: 1) During the quarter, MNK’s cash flow from operations was ~$279MM, with free cash flow of ~ $244MM. 2) MNK repurchased 9.4MM shares in 4Q17, or ~10% of outstanding shares in the last quarter. 3) Net debt was ~$5.5B, and MNK drew on its revolver in preparation for the SCMP (Not Covered) transaction. Net debt leverage was 4.0x as of the end of the year. 4) Acthar sales in the quarter were $295MM (FactSet consensus was $288MM), a 9.3% YoY decrease, affected by the previously disclosed patient withdrawal issues. MNK has taken a number of steps to address the issue, including engagement with payers, prescribers and patients. MNK remains focused on returning Acthar to growth. 5) MNK seeks to reduce its annual SG&A spending by $100MM no later than the early-2020s, while continuing to increase R&D spending." (2/27/2018)
3. According to Zacks Investment Research, "Mallinckrodt is selling its hemostasis products for Baxter. The company aims to focus better on its specialty pharmaceutical business after having sold its Nuclear Imaging business.Mallinckrodt is facing challenging conditions as lead drug Acthar sales declined on volume while weaknesses in the generics segment persist. Acthar declined as specialty drugs face payer environment and the decline is expected to continue in the fourth quarter as well. The company's generic segment continues to face weakness as various product categories are witnessing stiff competition, which is hurting both their volumes and prices. Shares of the company have underperformed the industry in the last six months. A U.S. District Court recently invalidated 11 patents covering its second-largest product Inomax. As a result, Mallinckrodt is looking to diversify its portfolio with the recently announced Sucampo acquisition and counter the decline in existing drugs." (1/9/2018)

Who are some of Mallinckrodt's key competitors?

Some companies that are related to Mallinckrodt include Hutchison China MediTech (HCM), Taro Pharmaceutical Industries (TARO), Loxo Oncology (LOXO), FibroGen (FGEN), GW Pharmaceuticals (GWPH), Advanced Accelerator Application (AAAP), Blueprint Medicines (BPMC), Ligand Pharmaceuticals (LGND), Tesaro (TSRO), Array BioPharma (ARRY), Emergent BioSolutions (EBS), Ultragenyx Pharmaceutical (RARE), Amicus Therapeutics (FOLD), Ascendis Pharma (ASND) and Evotec A.G. (EVTCY).

Who are Mallinckrodt's key executives?

Mallinckrodt's management team includes the folowing people:

Mr. Mark Christopher Trudeau, Pres, CEO & Director (Age 57)
Mr. Matthew K. Harbaugh, Exec. VP & CFO (Age 48)
Dr. Frank Scholz, Exec. VP of Global Operations & Pres of Specialty Generics (Age 49)
Mr. Hugh M. O'Neill, Exec. VP and Pres of Autoimmune & Rare Diseases (Age 55)
Dr. Gary M. Phillips, Exec. VP & Chief Strategy Officer (Age 52)

Has Mallinckrodt been receiving favorable news coverage?

Media headlines about MNK stock have trended somewhat positive recently, according to Accern Sentiment. The research firm rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Mallinckrodt earned a daily sentiment score of 0.13 on Accern's scale. They also gave news headlines about the company an impact score of 47.06 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Mallinckrodt?

Shares of MNK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mallinckrodt's stock price today?

One share of MNK stock can currently be purchased for approximately $13.52.

How big of a company is Mallinckrodt?

Mallinckrodt has a market capitalization of $1.16 billion and generates $3.22 billion in revenue each year. The company earns $2.13 billion in net income (profit) each year or $7.49 on an earnings per share basis. Mallinckrodt employs 3,900 workers across the globe.

How can I contact Mallinckrodt?

Mallinckrodt's mailing address is 3 LOTUS PARK THE CAUSEWAY, SURREY X0, TW18 3AG. The company can be reached via phone at 44-0-17-8463-6700 or via email at [email protected]

MarketBeat Community Rating for Mallinckrodt (MNK)

Community Ranking:		3.1 out of 5 ( )
Outperform Votes:		623 (Vote Outperform)
Underperform Votes:		371 (Vote Underperform)
Total Votes:		994

MarketBeat's community ratings are surveys of what our community members think about Mallinckrodt and other stocks. Vote "Outperform" if you believe MNK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNK will underperform the S&P 500 over the long term. You may vote once every thirty days.

Mallinckrodt (NYSE:MNK) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

18 Wall Street analysts have issued ratings and price targets for Mallinckrodt in the last 12 months. Their average twelve-month price target is $33.8333, suggesting that the stock has a possible upside of 150.25%. The high price target for MNK is $67.00 and the low price target for MNK is $15.00. There are currently 1 sell rating, 12 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Hold."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Hold	Hold	Hold	Buy
Consensus Rating Score:	2.22	2.33	2.39	2.78
Ratings Breakdown:	1 Sell Rating(s) 12 Hold Rating(s) 5 Buy Rating(s) 0 Strong Buy Rating(s)	1 Sell Rating(s) 10 Hold Rating(s) 7 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 11 Hold Rating(s) 7 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 4 Hold Rating(s) 14 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$33.8333	$38.50	$42.8056	$60.5278
Price Target Upside:	150.25% upside	144.13% upside	91.18% upside	86.70% upside

Mallinckrodt (NYSE:MNK) Consensus Price Target History

Price Target History for Mallinckrodt (NYSE:MNK)

Mallinckrodt (NYSE:MNK) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/26/2018	Mizuho	Reiterated Rating	Hold	$15.00	Low
4/23/2018	Leerink Swann	Lower Price Target	Market Perform		Low
4/12/2018	Stifel Nicolaus	Downgrade	Buy -> Hold	$50.00	High
4/12/2018	Wells Fargo	Reiterated Rating	Hold		High
4/11/2018	SunTrust Banks	Initiated Coverage	Hold	$15.00	High
4/2/2018	Cantor Fitzgerald	Set Price Target	Buy	$42.00	High
3/6/2018	Canaccord Genuity	Set Price Target	Hold	$20.00	High
2/27/2018	Oppenheimer	Reiterated Rating	Hold		High
2/2/2018	Barclays	Downgrade	Equal Weight -> Underweight	$23.00 -> $20.00	Medium
1/1/2018	Goldman Sachs	Reiterated Rating	Hold		High
11/26/2017	UBS	Downgrade	Buy -> Neutral	$70.00 -> $24.00	Medium
11/8/2017	Morgan Stanley	Lower Price Target	Equal Weight	$40.00 -> $27.00	N/A
11/8/2017	BMO Capital Markets	Lower Price Target	Outperform	$38.00	N/A
11/8/2017	Jefferies Group	Initiated Coverage	Market Perform -> Buy	$60.00 -> $30.00	N/A
11/7/2017	Citigroup	Downgrade	Buy -> Hold	$44.00 -> $28.00	N/A
11/7/2017	Deutsche Bank	Downgrade	Buy -> Hold	$44.00 -> $28.00	N/A
10/21/2017	Piper Jaffray	Set Price Target	Buy	$67.00	N/A
8/9/2017	Raymond James	Lower Price Target	Outperform	$65.00 -> $58.00	Low
4/1/2017	Guggenheim	Set Price Target	Buy	$98.00	Low
1/25/2017	JPMorgan Chase	Set Price Target	Hold	$78.00	N/A

(Data available from 4/26/2016 forward)

Mallinckrodt (NYSE:MNK) Earnings History and Estimates Chart

Earnings by Quarter for Mallinckrodt (NYSE:MNK)

Mallinckrodt (NYSE:MNK) Earnings Estimates

2018 EPS Consensus Estimate: $6.47

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	4	$1.08	$1.55	$1.22
Q2 2018	4	$1.51	$1.66	$1.58
Q3 2018	4	$1.58	$2.07	$1.78
Q4 2018	4	$1.80	$1.98	$1.90

Mallinckrodt (NYSE MNK) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/8/2018		$1.26					N/A
2/27/2018	Q4 2017	$1.72	$2.01	$769.91 million	$792.30 million	View	Listen
11/7/2017	Q3 2017	$1.80	$1.97	$808.93 million	$793.90 million	View	N/A
8/8/2017	Q2 2017	$1.73	$1.85	$829.56 million	$824.50 million	View	Listen
5/8/2017	Q1 2017	$1.63	$1.68	$781.23 million	$810.90 million	View	Listen
2/7/2017	Q117	$1.82	$1.91	$827.12 million	$829.90 million	View	Listen
11/29/2016	Q416	$1.98	$2.04	$880.10 million	$887.20 million	View	Listen
8/2/2016	Q316	$2.01	$2.20	$920.35 million	$970.60 million	View	Listen
5/3/2016	Q216	$1.72	$2.01	$878.70 million	$918.00 million	View	Listen
2/2/2016	Q116	$1.78	$2.09	$888.33 million	$915.00 million	View	Listen
11/23/2015	Q415	$1.77	$1.84	$869.41 million	$882.40 million	View	Listen
8/4/2015	Q315	$1.82	$2.05	$983.81 million	$965.10 million	View	Listen
5/5/2015	Q215	$1.48	$1.72	$860.89 million	$909.90 million	View	Listen
2/3/2015	Q115	$1.57	$1.84	$880.12 million	$866.00 million	View	Listen
11/19/2014	Q414	$1.41	$1.68	$759.04 million	$789.00 million	View	Listen
8/7/2014	Q314	$0.86	$1.20	$278.80 million	$653.10 million	View	Listen
5/8/2014	Q214	$0.79	$0.95	$566.50 million	$557.80 million	View	Listen
2/6/2014	Q1	$0.66	$0.88	$539.24 million	$540.20 million	View	Listen
11/7/2013		$0.85	$1.02	$572.57 million	$552.20 million	View	Listen
8/9/2013	Q3 2013	$0.78	$0.49	$557.22 million	$570.00 million	View	Listen

(Earnings results data provided by Zacks Investment Research)

Mallinckrodt (NYSE:MNK) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Mallinckrodt (NYSE MNK) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 1.80%

Insider Trading History for Mallinckrodt (NYSE:MNK)

Institutional Ownership by Quarter for Mallinckrodt (NYSE:MNK)

Mallinckrodt (NYSE MNK) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/28/2017	Dr Kneeland Youngblood	Director	Buy	4,560	$21.94	$100,046.40	19,789
11/13/2017	Joann A Reed	Director	Buy	1,000	$21.50	$21,500.00	15,554
11/13/2017	Steven J. Romano	VP	Buy	2,000	$21.96	$43,920.00
11/10/2017	Mark Trudeau	CEO	Buy	5,000	$22.28	$111,400.00
11/9/2017	David R Carlucci	Director	Buy	10,000	$21.83	$218,300.00	26,020
11/9/2017	Michael-Bryant Hicks	General Counsel	Buy	7,900	$20.80	$164,320.00
8/30/2017	Meredith B. Fischer	Insider	Buy	1,280	$39.63	$50,726.40
6/9/2017	Steven J. Romano	VP	Buy	1,000	$39.88	$39,880.00
6/8/2017	Hugh M. O'neill	VP	Buy	1,000	$40.24	$40,240.00
6/5/2017	Coleman N Lannum III	VP	Buy	500	$39.33	$19,665.00	31,455
6/2/2017	Coleman N Lannum III	VP	Buy	1,350	$42.89	$57,901.50	30,955
5/12/2017	Coleman N. Lannum III	VP	Buy	1,968	$46.20	$90,921.60
3/10/2017	Matthew K. Harbaugh	CFO	Buy	600	$49.19	$29,514.00
3/7/2017	Michael-Bryant Hicks	General Counsel	Buy	290	$50.35	$14,601.50
2/23/2017	Meredith B. Fischer	Insider	Buy	2,000	$54.34	$108,680.00
2/14/2017	Mark Trudeau	Insider	Buy	1,000	$50.47	$50,470.00
2/10/2017	Steven J. Romano	VP	Buy	1,000	$49.68	$49,680.00
5/10/2016	Hugh M O'neill	VP	Buy	1,653	$60.99	$100,816.47	15,623
5/10/2016	Matthew K Harbaugh	CFO	Buy	500	$59.37	$29,685.00	56,036
5/6/2016	Mark Trudeau	CEO	Buy	1,000	$56.02	$56,020.00	192,546
5/6/2016	Steven J Romano	VP	Buy	900	$56.00	$50,400.00	9,291
3/4/2016	Coleman N Lannum III	VP	Buy	2,600	$62.63	$162,838.00	20,556
2/26/2016	Meredith B Fischer	VP	Buy	1,400	$69.80	$97,720.00	17,643
2/12/2016	Coleman N Lannum III	VP	Buy	600	$59.66	$35,796.00	17,940
2/10/2016	Coleman N Lannum III	VP	Buy	1,300	$62.58	$81,354.00	17,340
2/9/2016	Matthew K. Harbaugh	CFO	Buy	1,300	$63.00	$81,900.00
2/8/2016	Coleman N. Lannum III	VP	Buy	800	$66.37	$53,096.00
12/22/2015	Coleman N Lannum III	SVP	Buy	500	$72.50	$36,250.00	11,266
12/11/2015	Terrance L Carlson	General Counsel	Buy	1,000	$69.10	$69,100.00	2,549
12/2/2015	Gary M. Phillips	VP	Buy	1,000	$72.17	$72,170.00	7,728
11/30/2015	Mark Trudeau	CEO	Buy	1,350	$65.89	$88,951.50	167,526
11/27/2015	Coleman N Lannum III	SVP	Buy	1,200	$66.86	$80,232.00	9,986
11/27/2015	Meredith B Fischer	VP	Buy	2,200	$66.93	$147,246.00	14,280
11/27/2015	Terrance L Carlson	General Counsel	Buy	1,000	$66.54	$66,540.00	1,453
8/25/2015	Hugh M O'neill	SVP	Buy	1,197	$83.52	$99,973.44	9,015
8/25/2015	Mark Trudeau	CEO	Buy	1,000	$83.08	$83,080.00	166,176
8/21/2015	Coleman N Lannum III	SVP	Buy	2,375	$88.52	$210,235.00	7,361
8/21/2015	Mark Trudeau	CEO	Buy	2,000	$88.45	$176,900.00	165,176
6/4/2015	Coleman N Lannum III	VP	Buy	1,300	$126.41	$164,333.00
6/2/2015	Matthew K Harbaugh	CFO	Sell	22,106	$128.64	$2,843,715.84
5/18/2015	Mario D Saltarelli	VP	Sell	4,580	$127.44	$583,675.20
5/13/2015	Don M Bailey	Director	Sell	51,417	$122.45	$6,296,011.65
5/11/2015	Sandra L Hatten	VP	Sell	2,024	$122.29	$247,514.96
4/13/2015	Don M Bailey	Director	Sell	40,000	$127.61	$5,104,400.00
3/13/2015	Don M Bailey	Director	Sell	40,000	$123.40	$4,936,000.00
2/13/2015	Don M Bailey	Director	Sell	33,891	$114.63	$3,884,925.33
2/2/2015	Mark Trudeau	CEO	Sell	11,925	$105.94	$1,263,334.50
1/9/2015	Mark Trudeau	CEO	Sell	15,720	$102.00	$1,603,440.00
12/22/2014	Peter G Edwards	VP	Sell	1,265	$99.69	$126,107.85
12/18/2014	Mark Trudeau	CEO	Sell	13,831	$93.59	$1,294,443.29
9/10/2014	Raymond J Furey	VP	Sell	5,441	$85.90	$467,381.90
9/8/2014	Don M Bailey	Director	Sell	221,177	$85.23	$18,850,915.71
9/5/2014	Raymond J Furey	VP	Sell	15,000	$85.47	$1,282,050.00
9/5/2014	Virgil D Thompson	Director	Sell	25,000	$83.76	$2,094,000.00
9/2/2014	Raymond J Furey	VP	Sell	10,303	$81.61	$840,827.83
8/29/2014	Raymond J Furey	VP	Sell	4,840	$80.90	$391,556.00
8/19/2014	Joseph A Zaccagnino	Director	Buy	3,000	$71.06	$213,180.00
8/13/2014	Paulson & Co Inc	Major Shareholder	Buy	132,100	$69.80	$9,220,580.00
8/12/2014	J Martin Carroll	Director	Buy	2,000	$69.24	$138,480.00
8/12/2014	Paulson & Co Inc	Major Shareholder	Buy	467,900	$68.78	$32,182,162.00
8/11/2014	Paulson & Co Inc	Major Shareholder	Buy	207,900	$69.70	$14,490,630.00
8/7/2014	Paulson & Co Inc	Major Shareholder	Buy	700,200	$70.15	$49,119,030.00
8/1/2014	Paulson & Co Inc	Major Shareholder	Buy	275,000	$69.60	$19,140,000.00
6/11/2014	Melvin D Booth	Director	Buy	4,000	$76.05	$304,200.00
5/9/2014	Paulson & Co Inc	major shareholder	Buy	786,207	$73.63	$57,888,421.41
2/3/2014	Mark Trudeau	CEO	Sell	14,890	$56.12	$835,626.80

(Data available from 1/1/2013 forward)

Mallinckrodt (NYSE MNK) News Headlines

Source:

Date	Headline
	Mizuho Reiterates "Hold" Rating for Mallinckrodt (MNK) www.americanbankingnews.com - April 26 at 4:22 PM
	Leerink Swann Comments on Mallinckrodt's FY2019 Earnings (MNK) www.americanbankingnews.com - April 26 at 11:05 AM
	Mallinckrodt (MNK) Price Target Cut to $0.00 www.americanbankingnews.com - April 23 at 10:23 AM
	Mallinckrodt: Are Bondholders Predicting Impending Doom? seekingalpha.com - April 21 at 5:03 PM
	Mallinckrodt's (MNK) Hold Rating Reiterated at Mizuho www.americanbankingnews.com - April 20 at 11:53 AM
	UBS Reiterates "Buy" Rating for Mallinckrodt (MNK) www.americanbankingnews.com - April 20 at 11:19 AM
	Mallinckrodt To Present At UBS Global Healthcare Conference finance.yahoo.com - April 20 at 8:46 AM
	Q4 2018 Earnings Forecast for Mallinckrodt (MNK) Issued By Leerink Swann www.americanbankingnews.com - April 18 at 8:39 AM
	Mallinckrodt (MNK) PT Set at $87.00 by Canaccord Genuity www.americanbankingnews.com - April 17 at 10:21 PM
	Are The Shorts Right About Mallinckrodt? seekingalpha.com - April 17 at 5:39 PM
	U.S. drug agency proposes rules to rein in opioid manufacturing finance.yahoo.com - April 17 at 5:39 PM
	Brokers Issue Forecasts for Mallinckrodt's Q1 2018 Earnings (MNK) www.americanbankingnews.com - April 17 at 6:51 AM
	BRIEF-Mallinckrodt Announces $300 Million Debt Repayment www.reuters.com - April 16 at 5:06 PM
	Whistleblower Claims Mallinckrodt Is Scheming To Spike Acthar Sales seekingalpha.com - April 16 at 5:06 PM
	Mallinckrodt plc Announces $300 Million Debt Repayment finance.yahoo.com - April 16 at 5:06 PM
	Q1 2018 Earnings Estimate for Mallinckrodt (MNK) Issued By SunTrust Banks www.americanbankingnews.com - April 16 at 1:19 AM
	Zacks Investment Research Upgrades Mallinckrodt (MNK) to Hold www.americanbankingnews.com - April 15 at 6:44 PM
	$570.67 Million in Sales Expected for Mallinckrodt (MNK) This Quarter www.americanbankingnews.com - April 14 at 4:20 AM
	Mallinckrodt's (MNK) Buy Rating Reiterated at Jefferies Group www.americanbankingnews.com - April 13 at 11:42 PM
	The Mallinckrodt/Acthar Mess Has Only Just Begun And Could Be Bigger Than Anyone Could Imagine (Podcast) seekingalpha.com - April 13 at 5:14 PM
	Mallinckrodt (MNK) PT Set at $85.00 by Piper Jaffray www.americanbankingnews.com - April 13 at 12:58 AM
	Mallinckrodt (MNK) Stock Rating Lowered by BidaskClub www.americanbankingnews.com - April 12 at 6:14 PM
	Mallinckrodt shares slide on whistleblower lawsuit involving its best-selling drug www.cnbc.com - April 12 at 2:58 PM
	Mallinckrodt (MNK) Receives Hold Rating from Stifel Nicolaus www.americanbankingnews.com - April 12 at 2:19 PM
	Mallinckrodt (MNK) Rating Reiterated by Wells Fargo www.americanbankingnews.com - April 12 at 1:16 PM
	Mallinckrodt (MNK) Given a $87.00 Price Target by Canaccord Genuity Analysts www.americanbankingnews.com - April 12 at 11:27 AM
	Brokerages Expect Mallinckrodt (MNK) Will Announce Earnings of $1.14 Per Share www.americanbankingnews.com - April 12 at 8:47 AM
	UBS Analysts Give Mallinckrodt (MNK) a $70.00 Price Target www.americanbankingnews.com - April 11 at 11:52 PM
	Deutsche Bank Analysts Give Mallinckrodt (MNK) a $56.00 Price Target www.americanbankingnews.com - April 11 at 7:18 PM
	Mallinckrodt (MNK) Coverage Initiated by Analysts at SunTrust Banks www.americanbankingnews.com - April 11 at 5:35 PM
	'There's other s--- in the vial': Bombshell lawsuit claims no one knows exactly what's in a drug that's cost the ... www.businessinsider.com - April 11 at 5:11 PM
	Mallinckrodt To Present At Deutsche Bank's 43rd Annual Healthcare Conference finance.yahoo.com - April 9 at 8:46 AM
	ValuEngine Upgrades Mallinckrodt (MNK) to "Buy" www.americanbankingnews.com - April 8 at 11:48 AM
	Mallinckrodt (MNK) Expected to Earn FY2018 Earnings of $6.03 Per Share www.americanbankingnews.com - April 6 at 6:54 AM
	Form 4 Mallinckrodt plc For: Apr 02 Filed by: O'Neill Hugh M. www.streetinsider.com - April 5 at 10:39 AM
	Form 4 Mallinckrodt plc For: Apr 02 Filed by: LLOYD RONALD K. www.streetinsider.com - April 5 at 10:39 AM
	Mallinckrodt (MNK) Given Average Recommendation of "Hold" by Analysts www.americanbankingnews.com - April 5 at 5:34 AM
	BRIEF-Mallinckrodt Names Paul Carter, Anne Whitaker To Its Board Of Directors www.reuters.com - April 4 at 8:41 AM
	Angus Russell to Succeed Melvin Booth as Mallinckrodt Chairman of the Board in May 2018 finance.yahoo.com - April 4 at 8:41 AM
	Mallinckrodt Names Paul R. Carter, Anne C. Whitaker to its Board of Directors finance.yahoo.com - April 4 at 8:41 AM
	Mallinckrodt (MNK) Downgraded by ValuEngine to "Sell" www.americanbankingnews.com - April 3 at 12:10 PM
	Mallinckrodt (MNK) Given a $42.00 Price Target by Cantor Fitzgerald Analysts www.americanbankingnews.com - April 3 at 10:37 AM
	Mallinckrodt's (MNK) Buy Rating Reiterated at Cantor Fitzgerald www.americanbankingnews.com - April 1 at 11:24 PM
	Mallinckrodt (MNK) Raised to Hold at Zacks Investment Research www.americanbankingnews.com - April 1 at 7:35 PM
	Mallinckrodt (MNK) Stock Rating Lowered by Wells Fargo www.americanbankingnews.com - April 1 at 11:24 AM
	Mallinckrodt (MNK) Receives New Coverage from Analysts at Jefferies Group www.americanbankingnews.com - April 1 at 11:24 AM
	Barclays Downgrades Mallinckrodt (MNK) to Equal Weight www.americanbankingnews.com - April 1 at 11:23 AM
	Goldman Sachs Downgrades Mallinckrodt (MNK) to Neutral www.americanbankingnews.com - April 1 at 10:48 AM
	BMO Capital Markets Trims Mallinckrodt (MNK) Target Price to $38.00 www.americanbankingnews.com - April 1 at 10:48 AM
	Mallinckrodt (MNK) PT Lowered to $50.00 www.americanbankingnews.com - April 1 at 9:47 AM

Mallinckrodt (NYSE:MNK) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Mallinckrodt (NYSE:MNK) Income Statement, Balance Sheet and Cash Flow Statement

Mallinckrodt (NYSE MNK) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff